SCHEMBL4059595

SCHEMBL4059595

CCOc1cccc(-c2nc3ncc(-c4ccccc4)cc3[nH]2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 3/20 0.56
KDM4E B2RXH2 1/20 0.56
NPC1 O15118 1/20 0.56
USP2 O75604 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
HPGD P15428 1/20 0.56
TSHR P16473 1/20 0.56
NFKB1 P19838 1/20 0.56
RAB9A P51151 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
HSD17B10 Q99714 1/20 0.56
FGFR1 P11362 2/20 0.55
FGFR2 P21802 1/20 0.55
FGFR3 P22607 1/20 0.55
AURKA O14965 4/20 0.52
NOS3 P29474 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053057 0.90 AURKA (0.50) TP53SMN1; SMN2MAPTKDM4ENPC1
SCHEMBL4053339 0.89 AURKA (0.50) TP53SMN1; SMN2MAPTKDM4ENPC1
SCHEMBL4055330 0.89 AURKA (0.67) TP53SMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL4049461 0.88 SCD (0.52) TP53SMN1; SMN2MAPTKDM4ENPC1
SCHEMBL4052666 0.87 PPARG (0.49) TSHRAURKANOS3NOS1NOS2
SCHEMBL4063060 0.87 DHODH (0.53) AURKANOS3NOS1NOS2TBK1
SCHEMBL4055311 0.87 AURKA (0.49) TP53SMN1; SMN2MAPTKDM4ENPC1
SCHEMBL4058201 0.86 SMN1; SMN2 (0.55) TP53SMN1; SMN2MAPTKDM4ENPC1
SCHEMBL4054953 0.86 FGFR1 (0.49) TP53SMN1; SMN2MAPTKDM4ENPC1
SCHEMBL4061348 0.86 AURKA (0.46) TP53SMN1; SMN2MAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B TP53 842/4885SMN1; SMN2 4289/4885MAPT 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.